// App-Quantinova.ai

BSH2020‐PO‐079 : Impact of stopping long‐term immunoglobulin therapy in haematological secondary antibody deficiency

Researchers

Presenter

  • S. Goddard

Principal Investigators

  • D. Hughes

  • L. Diwakar

  • J. Graham

Medical Centers

  • Inmunology

  • Haematology, University Hospitals North Midlands, Stoke‐on‐Trent, UK

Locations

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Infectious Diseases (ID)

  • Endocrine/metabolic Diseases (ME)

  • Oncology (ONC)

  • Autoimmune (AI)

Disease

  • Chronic Lymphocytic Leukemia

  • Waldenstrom’s macroglobulinemia

  • Lympho proliferative disease

  • Mucosa-associated lymphoid tissue lymphoma

  • Monoclonal gammopathy

  • Hodgkin's Lymphoma

  • Lung Cancer

  • Influenza

  • Lymphomas

  • Solid malignancies

  • Post-transplant lymphoproliferative disorder

Biomarkers

  • Immunoglobulin G

  • Monoclonal gammopathy of undetermined significance

Drug/Treatment

  • Intratect

  • Azithromycin

  • Doxycycline

  • Trimethoprim and sulfamethoxazole

  • IVIG

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved